Nuclear Medicine & Radiation Therapy

MRA Pillai

Publications

• Research Article
  Preparation of [177Lu]PSMA-617 Using Carrier Added (CA) 177Lu for Radionuclide Therapy of Prostate Cancer
  Author(s): Raviteja Nanabala, Arun Sasikumar, Ajith Joy and MRA PillaiRaviteja Nanabala, Arun Sasikumar, Ajith Joy and MRA Pillai
  
  Objective: Lutetium-177 labelled PSMA-617 is an emerging radiopharmaceutical for targeted radionuclide therapy of prostate cancer (PCa) and hence there is an interest in the formulation and clinical application of this novel tracer. This paper summarises the studies undertaken to prepare clinical doses of [177Lu]PSMA-617 for therapy of prostate cancer patients. Experimental: [177Lu]PSMA-617 was prepared by reacting 177LuCl3 (5.4 GBq to 15.8 GBq, specific activity 650 MBq/μg to 860 MBq/μg) with 100 μg to 300 μg of PSMA-617 at pH 4.5-5. Radiochemical (RC) yields were estimated by thin layer and paper chromatography. When RC yields were lower than 95% the product was purified using a C18 cartridge which removed unreacted 177LuCl3. Two patients having histopathologically proven PCa and having significant levels of metastasis were given freshly.. Read More»
  DOI: 10.4172/2155-9619.1000306

  Abstract PDF